Intracoronary cardiosphere-derived stem cell therapy (Capricor)

N/A

Report date: 2022/09/05 20:00:48

Base Information

Drug NameIntracoronary cardiosphere-derived stem cell therapy (Capricor)
Drug Alias NameCPI-003CAP-1001
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsVentricular Dysfunction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCapricor Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthCedars-Sinai Medical CenterJohns Hopkins University +[4] 
Active IndicationsN/A
Inactive IndicationsVentricular Dysfunction

Other Information

ATC CodeN/A
Related LinksN/A